Enterprise Value
442.8M
Cash
241.3M
Avg Qtr Burn
-43.04M
Short % of Float
28.43%
Insider Ownership
11.23%
Institutional Own.
99.68%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease | Phase 4 Data readout | |
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD) | Approved Quarterly sales | |
TRELEGY ELLIPTA Details Asthma | Approved Quarterly sales | |
AMPRELOXETINE (TD-9855) Details Hypotension | Phase 3 Data readout | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Crohns disease, Ulcerative colitis | Phase 2/3 Update | |
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder | Phase 2 Update | |
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease | Phase 2 Update |